Zoetis recently received a positive opinion from the European Medicines Agency’s CVMP for its pain relief therapy, Portela, expected to enhance its product line for feline osteoarthritis. The company also secured a new $1.25 billion revolving credit facility to bolster its financial flexibility. These developments come amid a mixed market environment where the Nasdaq reached new highs. Despite these advancements, Zoetis’ stock declined 3% last month, reflecting broader market dynamics rather than specific corporate events. The company’s moves could provide long-term benefits, but they did not counteract overall market trends.
ZTS Earnings Per Share Growth as at Sep 2025
Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
The recent positive developments, such as the approval of Portela by the European Medicines Agency’s CVMP, and the new US$1.25 billion revolving credit facility, bolster Zoetis’ financial flexibility and product portfolio, potentially impacting future revenue streams. These initiatives emphasize the company’s commitment to addressing unmet demand within the animal health sector, which could enhance its product offerings and expand market share. Although promising, these factors have not countered current market trends, influencing the company’s recent short-term stock decline.
Over the longer term, Zoetis’ total shareholder return, including dividends, was 2.84% over a three-year period—indicating the share price and dividend performance contextually. This decline contrasts with the company’s short-term price performance, where Zoetis underperformed the broader US Pharmaceuticals industry by a significant margin over the past year, which returned a substantial decrease. Such performance underscores the broader market challenges rather than specific issues within Zoetis, despite its sound business fundamentals.
The news about Zoetis’ recent initiatives could positively affect revenue and earnings forecasts in the future. However, analysts have projected modest revenue growth of 5.2% annually over the next few years, which is less than the broader market growth expectations. Although earnings are slated to grow to US$3.2 billion by 2028, the current share price of US$148.20 remains below the analyst consensus price target of US$190.29, suggesting potential upside if the company’s growth projections materialize. As the current discount to the analyst target price is significant, how Zoetis navigates regulatory and market challenges will likely influence future performance.
Story Continues
Explore historical data to track Zoetis’ performance over time in our past results report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZTS.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com